UNITAID is inviting letters of intent (LOI), or short conceptual presentations of a proposed project, on the topic of improving access to key preventive, diagnostic and treatment commodities for HIV, tuberculosis (TB) and malaria through market-based approaches.  UNITAID works to negotiate low pricing for diagnostics and medication for AIDS, tuberculosis and malaria in developing countries and is funded primarily by an airline levy in participating countries.

The words ‘defaulter’, ‘suspect’ and ‘control’ have been part of the language of tuberculosis (TB) services for many decades, and they continue to be used in international guidelines and published literature.

The worldwide counterfeit drug market is huge and growing. The Center for Medicine in the Public Interest estimates that in 2010 the trade reaped around $75 billion, a 90 percent increase since 2005. Over the same period, the Pharmaceutical Security Institute (PSI), of which one of us is president, documented a huge increase in discoveries of counterfeit pharmaceutical products. In 2005, it recorded over 1,000 incidents; in 2010, it recorded more than twice that. The World Health Organization previously estimated that as much as 15 percent of the medicine in circulation around the world could be fake. These drugs occupy a wide spectrum of medications, and their quality is suspect; they can be mislabeled, tainted, adulterated, ineffective, or, in the worst cases, all of the above.

HIV & AIDS treatment in practice (HATIP) is a regular email newsletter for healthcare workers and community-based organisations on HIV treatment in resource-limited settings.

Quantifying the effect of antiretroviral therapy (ART) on the incidence of tuberculosis (TB) in HIV-infected patients has been difficult. Several studies have shown a lower rate of TB among HIV-infected patients who are receiving ART than among those who are not. However, during the first few months of treatment, TB rates may be elevated because of immune reconstitution inflammatory syndrome (IRIS).

Interferon-gamma release assays (IGRAs) are significantly better than tuberculin skin tests (TST) at predicting progression from latent tuberculosis (TB), a new meta-analysis from Germany shows.

A third of the world's population is carrying tuberculosis, and the disease could become incurable if governments fail to act, the World Health Organisation (WHO) has warned. Lack of funding for public health programmes, the sale of inaccurate blood tests and the misuse of drugs, particularly in the private health sector, are hampering the fight against the disease and leading to drug resistance, says the organisation.

A Digital Chest X-ray machine, which communicates directly with the central level from anywhere in the country, will be used for the TB Prevalence survey.

Between 1990 and 2010, in countries with tuberculosis (TB) programs supported by USAID, TB death rates decreased by 29 percent, and TB prevalence rates declined by 14 percent.

Through spearheading innovative initiatives and providing financing for global health over the past five years, UNITAID has had a dramatic impact on millions of lives, using creative market approaches to increase access to treatment and diagnostics for HIV, malaria and tuberculosis.